Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Viemed Healthcare Inc VMD

Viemed Healthcare, Inc. through its subsidiaries, is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counselling to patients in their homes using cutting edge technologies. The Company’s products and services... see more

NDAQ:VMD - Post Discussion

Viemed Healthcare Inc > RBC Reaction
View:
Post by retiredcf on May 25, 2021 7:06am

RBC Reaction

May 24, 2021

Price Target USD 13.00

VieMed Healthcare, Inc.

OIG report looks scary, but we expect little to come from it

Our View: While the OIG report could cause some stock price volatility, mgmt is confident in its position and does not anticipate booking a liability.

First impression: The U.S. Department of Health and Human Services Office of Inspector General (OIG) on Friday issued a report stating that most of the company's Medicare claims for monthly rental of non-invasive ventilators did not comply with regulations.

The OIG audited claims for 100 patients and states that 98 were non- compliant, and then extrapolates to estimate overpayments of $29.1MM from 2016-2017.

VMD has issued a strong response to the OIG's report, noting that 42 of the 100 patient claims had already been audited by a CMS contractor as part of a prepayment review, which approved 41 of the 42 claims.

Importantly, the OIG is not alleging fraudulent activity, so the "reopening period" is limited to four years.

As such, the majority of the claims for the 2016-2017 period in question have already lapsed the window, and management estimates the $29.1MM figure is already down to $11MM, and continuing to decline with the passage of time.

Given its strong confidence in the company's compliance with regulatory requirements, management does not expect to receive an overpayment determination from CMS, and does not anticipate booking a liability on the balance sheet for this matter.

Note also that the OIG does not set clinical policy and its powers are limited to recommending that CMS take action.

The final decision on whether to issue an overpayment determination and recoup any funds lies with CMS, and at this point it is not clear when this issue could reach some sort of resolution.

Comment by JackLambert on May 25, 2021 7:53am
Good catch.   This thing smells of an agenda - there's no reasonable expectation of a fraud conviction here.   In the popular idiom of this godless age - they are just p*ssing on our hydrant.   But why?   The outcome will not get the OIG a cheque.  So why bother.  Any one who thinks audit is free of political chicanery has not been around long enough   ...more  
Comment by lscfa on May 25, 2021 8:00am
VMD stock traded higher in US yesterday.
Comment by donmayne on May 25, 2021 8:56am
In the long term, the OIG report will speed the determination of the medical appropriateness of NIV.  With Covid, attention has focused on whether invasive vents have done more harm than good and many jurisdictions have instituted protocols preferring NIV treatment patients. The Viemed published study on patient outcomes using NIV was strategic and authoritative guaranteeing robust growth in ...more  
Comment by lscfa on May 25, 2021 1:54pm
Bozo move not to put this in the news release.   Readers will think there is a possible $29 million overpayment that needs to repaid.    As such, the majority of the claims for the 2016-2017 period in question have already lapsed the window, and management estimates the $29.1MM figure is already down to $11MM, and continuing to decline with the passage of time.
Comment by besttobe on May 31, 2021 11:40am
For you Longterm..quite per below "The final decision on whether to issue an overpayment determination and recoup any funds lies with CMS, and at this point it is not clear when this issue could reach some sort of resolution." May 24, 2021 Price Target USD 13.00 VieMed Healthcare, Inc. OIG report looks scary, but we ...more  
Comment by besttobe on May 31, 2021 12:38pm
For you Longterm. Quote from NR that says CMS has not made a determination and why ISCFA has said they left the decision in limbo in the NR per the his below quote nd RBC also saying it is limbo....(all public knowledge and why the S/P is tanking) The Report is not binding on the Centers for Medicare & Medicaid Services (“CMS”), and the Company has received no indication that CMS intends to ...more